Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multiparametric Prediction Models for Coronavirus Disease 2019 Vaccine Selection: Results of a Comparative Population-Based Cohort Study.
Sieghart D, Hana CA, Haslacher H, Perkmann T, Heinz LX, Fedrizzi C, Anderle K, Wiedermann U, Condur I, Drapalik S, Steinbrecher H, Mrak D, Mucher P, Hasenoehrl T, Zrdavkovic A, Wagner B, Palma S, Jordakieva G, Jorda A, Firbas C, Wagner A, Haiden N, Bergmann F, Crevenna R, Zeitlinger M, Bonelli M, Aletaha D, Radner H. Sieghart D, et al. Among authors: fedrizzi c. Clin Infect Dis. 2023 Mar 4;76(5):816-823. doi: 10.1093/cid/ciac840. Clin Infect Dis. 2023. PMID: 36328594
Reduced immunogenicity of BNT162b2 booster vaccination in combination with a tetravalent influenza vaccination: results of a prospective cohort study in 838 health workers.
Radner H, Sieghart D, Jorda A, Fedrizzi C, Hasenöhrl T, Zdravkovic A, Redlberger-Fritz M, Puchammer-Stoeckl E, Anderle K, Bergmann F, Firbas C, Jordakieva G, Wagner B, Haslacher H, Perkmann T, Heinz LX, Bonelli M, Crevenna R, Aletaha D, Zeitlinger M. Radner H, et al. Among authors: fedrizzi c. Clin Microbiol Infect. 2023 May;29(5):635-641. doi: 10.1016/j.cmi.2022.12.008. Epub 2022 Dec 9. Clin Microbiol Infect. 2023. PMID: 36509374 Free article. Clinical Trial.
Immunogenicity and safety of COVID-19 booster vaccination: A population-based clinical trial to identify the best vaccination strategy.
Sieghart D, Hana CA, Dürrschmid C, Heinz LX, Haslacher H, Zlesak M, Piccini G, Manenti A, Montomoli E, Jorda A, Fedrizzi C, Hasenoehrl T, Zdravkovic A, Anderle K, Wiedermann U, Drapalik S, Steinbrecher H, Bergmann F, Firbas C, Jordakieva G, Wagner B, Leonardi M, Pierleoni G, Ballini M, Benincasa L, Marchi S, Trombetta C, Perkmann T, Crevenna R, Zeitlinger M, Bonelli M, Aletaha D, Radner H. Sieghart D, et al. Among authors: fedrizzi c. J Clin Virol. 2024 Feb 28;173:105661. doi: 10.1016/j.jcv.2024.105661. Online ahead of print. J Clin Virol. 2024. PMID: 38503118